CG
SYRE icon

Carlyle Group’s Spyre Therapeutics SYRE Stock Holding History

Carlyle Group’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-9,620
Closed -$485K – 21
2026
Q1 		$485K Hold
9,620
– – ﹤0.01% 17
2025
Q4 		$315K Buy
+9,620
New +$251K ﹤0.01% 19
2025
Q1 		– Sell
-9,620
Closed -$224K – 27
2024
Q4 		$224K Hold
9,620
– – 0.01% 25
2024
Q3 		$282K Hold
9,620
– – 0.03% 25
2024
Q2 		$227K Hold
9,620
– – 0.02% 27
2024
Q1 		$365K Hold
9,620
– – 0.02% 28
2023
Q4 		$204K Buy
+9,620
New +$133K 0.01% 23
2023
Q3 		– Sell
-9,620
Closed -$108K – 26
2023
Q2 		$108K Hold
9,620
– – ﹤0.01% 25
2023
Q1 		$69K Buy
+9,620
New +$106K ﹤0.01% 30

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Carlyle Group's SYRE Position: Q2 2026 in Review

Carlyle Group sold out of Spyre Therapeutics (SYRE) in Q2 2026, closing a stake of 9,620 shares — an estimated $485K sold.

Carlyle Group first reported a position in SYRE in Q1 2023 and held it in 9 quarters. The position peaked at $485K in Q1 2026. 266 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Carlyle Group reported no remaining Spyre Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Carlyle Group sold 9,620 Spyre Therapeutics shares in Q2 2026, an estimated $485K.
  • Carlyle Group first reported a position in Spyre Therapeutics in Q1 2023 and held it in 9 quarters.
  • Carlyle Group's Spyre Therapeutics position peaked at $485K in Q1 2026.
  • 266 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Carlyle Group's 13F filing for Q2 2026, filed 7 Aug 2026.